Jordan-based Tabuk Pharmaceuticals Manufacturing Company said it has signed an asset purchase agreement along with a supply agreement with Swiss group Acino Pharma AG.

Under this agreement, Acino will acquire three of Tabuk's existing products in the cardiovascular therapy area in Saudi Arabia, the Gulf Countries and Middle East and North Africa (Mena) region, excluding Morocco, Sudan and Algeria.

This project will allow Acino to continue on these products' success, to expand the offering of cardiovascular medicines in Saudi Arabia and the Mena region, and to reach more patients.

"This partnership illustrates our commitment to leverage our Mena-wide footprint and to serve multinational partners looking to maximize their potential in the region," remarked Georges De Vos, the chief executuve of Tabuk Pharmaceuticals.

Dr Rana Azzam, the senior VP of Business Development, said: "We are delighted to be collaborating with Acino, one of the fastest growing branded generic companies in the region, this will for sure help us to expand our partners network worldwide. Such partnerships will for sure help us to serve our patients better."

Acino CEo Kalle Känd expressed delight at establishing a relationship with Tabuk, a major player in the pharmaceutical landscape in Saudi Arabia and the Middle East.

"With this partnership, we are adding products with existing sales to our key countries in this region and can provide a richer portfolio of medicines for our patients," he added.-TradeArabia News Service